Want to see HK:8158 full AI Analyst Report?
China Regenerative Medicine International Limited (8158) Ratios
China Regenerative Medicine International Limited Ratios
HK:8158's free cash flow for Q2 2026 was $-1.97M. For the 2026 fiscal year, HK:8158's free cash flow was increased by $0.00 and operating cash flow was $-1.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.14 | 0.99 | 1.14 | 1.57 | 1.75 |
| Quick Ratio | 1.12 | 0.99 | 1.14 | 1.57 | 1.75 |
| Cash Ratio | 0.11 | 0.39 | 0.02 | 0.01 | 0.07 |
| Solvency Ratio | 0.33 | 0.26 | -0.55 | 0.06 | 0.35 |
| Operating Cash Flow Ratio | 0.05 | 0.31 | 0.04 | -0.11 | -0.02 |
| Short-Term Operating Cash Flow Coverage | 1.13 | 5.04 | 0.47 | -0.36 | -0.10 |
| Net Current Asset Value | $ -28.55M | $ -52.20M | $ -5.53M | $ 77.10M | $ 110.97M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.40 | 0.27 | 0.26 | 0.14 |
| Debt-to-Equity Ratio | 0.96 | 2.13 | 4.26 | 0.69 | 0.32 |
| Debt-to-Capital Ratio | 0.49 | 0.68 | 0.81 | 0.41 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.33 | 0.64 | 0.65 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.14 | 5.39 | 15.76 | 2.66 | 2.32 |
| Debt Service Coverage Ratio | -0.84 | 6.27 | -6.53 | 0.22 | 1.72 |
| Interest Coverage Ratio | 13.63 | 16.28 | -111.45 | 15.74 | 80.11 |
| Debt to Market Cap | 0.24 | 0.55 | 0.22 | 0.15 | 0.04 |
| Interest Debt Per Share | 0.17 | 0.18 | 0.18 | 0.26 | 0.13 |
| Net Debt to EBITDA | 5.22 | 1.04 | -0.49 | 4.86 | 0.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 58.17% | 63.62% | 27.95% | 90.58% | 23.94% |
| EBIT Margin | -2.21% | 20.84% | -153.58% | 21.78% | 22.99% |
| EBITDA Margin | 11.47% | 32.93% | -137.30% | 34.76% | 23.01% |
| Operating Profit Margin | 22.75% | 20.33% | -157.03% | 29.59% | 20.84% |
| Pretax Profit Margin | 21.08% | 19.59% | -154.99% | 19.90% | 22.73% |
| Net Profit Margin | 38.20% | 19.59% | -154.99% | 10.97% | 18.32% |
| Continuous Operations Profit Margin | 38.20% | 19.59% | -154.99% | 10.97% | 18.32% |
| Net Income Per EBT | 181.22% | 100.00% | 100.00% | 55.10% | 80.61% |
| EBT Per EBIT | 92.66% | 96.34% | 98.70% | 67.26% | 109.04% |
| Return on Assets (ROA) | 16.38% | 13.08% | -57.93% | 1.65% | 20.00% |
| Return on Equity (ROE) | 51.47% | 70.45% | -913.25% | 4.38% | 46.39% |
| Return on Capital Employed (ROCE) | 17.66% | 23.98% | -286.33% | 10.44% | 52.72% |
| Return on Invested Capital (ROIC) | 2.93% | 21.66% | -175.62% | 3.85% | 32.19% |
| Return on Tangible Assets | 16.38% | 13.08% | -57.93% | 1.65% | 20.00% |
| Earnings Yield | 21.54% | 19.76% | -68.37% | 1.44% | 6.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.24 | 145.69 | 0.44 | 0.17 | 1.44 |
| Payables Turnover | 10.04 | 8.58 | 20.24 | 73.85 | 2417.64 |
| Inventory Turnover | 14.82 | 139.67 | 112.50 | 13.69 | 560.34 |
| Fixed Asset Turnover | 3.11 | 12.97 | 4.01 | 1.55 | 375.69 |
| Asset Turnover | 0.43 | 0.67 | 0.37 | 0.15 | 1.09 |
| Working Capital Turnover Ratio | 14.05 | 8.96 | 1.24 | 0.41 | 10.56 |
| Cash Conversion Cycle | 282.45 | -37.41 | 813.19 | 2111.20 | 254.83 |
| Days of Sales Outstanding | 294.19 | 2.51 | 827.97 | 2089.47 | 254.33 |
| Days of Inventory Outstanding | 24.63 | 2.61 | 3.24 | 26.67 | 0.65 |
| Days of Payables Outstanding | 36.37 | 42.53 | 18.03 | 4.94 | 0.15 |
| Operating Cycle | 318.82 | 5.12 | 831.22 | 2116.14 | 254.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | 0.06 | 0.02 | -0.06 | -0.01 |
| Free Cash Flow Per Share | 0.01 | 0.06 | 0.02 | -0.07 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 58.51 | 29.19 | 23.13 | -6.81 | -3.74 |
| Capital Expenditure Coverage Ratio | 58.51 | 29.19 | 23.13 | -6.81 | -3.74 |
| Operating Cash Flow Coverage Ratio | 0.08 | 0.34 | 0.13 | -0.25 | -0.08 |
| Operating Cash Flow to Sales Ratio | 0.06 | 0.20 | 0.09 | -0.43 | -0.01 |
| Free Cash Flow Yield | 3.15% | 19.68% | 3.85% | -6.39% | -0.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 4.64 | 5.06 | -1.46 | 69.56 | 15.42 |
| Price-to-Sales (P/S) Ratio | 1.77 | 0.99 | 2.27 | 7.63 | 2.83 |
| Price-to-Book (P/B) Ratio | 2.39 | 3.56 | 13.36 | 3.05 | 7.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 31.74 | 5.08 | 25.98 | -15.65 | -208.61 |
| Price-to-Operating Cash Flow Ratio | 31.20 | 4.91 | 24.85 | -17.95 | -264.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | -0.04 | 0.00 | -0.76 | -0.14 |
| Enterprise Value Multiple | 20.68 | 4.05 | -2.14 | 26.80 | 12.67 |
| Enterprise Value | 170.92M | 120.81M | 204.38M | 386.99M | 825.10M |
| EV to EBITDA | 20.68 | 4.05 | -2.14 | 26.80 | 12.67 |
| EV to Sales | 2.37 | 1.33 | 2.94 | 9.32 | 2.92 |
| EV to Free Cash Flow | 42.45 | 6.83 | 33.70 | -19.12 | -215.37 |
| EV to Operating Cash Flow | 41.73 | 6.60 | 32.25 | -21.92 | -273.03 |
| Tangible Book Value Per Share | 0.18 | 0.08 | 0.04 | 0.36 | 0.39 |
| Shareholders’ Equity Per Share | 0.18 | 0.08 | 0.04 | 0.36 | 0.39 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.81 | 0.00 | 0.00 | 0.45 | 0.19 |
| Revenue Per Share | 0.24 | 0.30 | 0.24 | 0.15 | 0.99 |
| Net Income Per Share | 0.09 | 0.06 | -0.38 | 0.02 | 0.18 |
| Tax Burden | 1.81 | 1.00 | 1.00 | 0.55 | 0.81 |
| Interest Burden | -9.53 | 0.94 | 1.01 | 0.91 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.59 | 0.57 | 0.56 | 0.53 | 0.15 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Income Quality | 0.15 | 1.03 | -0.06 | -2.14 | -0.12 |
Currency in HKD